OpenAI acquires AI drug development platform
OpenAI has acquired Orchestra Bio, an AI-powered platform that helps biopharma teams coordinate the drug development process. OpenAI announced the deal Oct. 20 and did not disclose financial terms. The company plans to combine Orchestra’s team and technology with Rosalind, its suite of AI models and tools for life sciences research, which includes the GPT-Rosalind […] The post OpenAI acquires AI drug development platform appeared first on Becker's Hospital Review | Healthcare News &am...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.